通过靶向 Bcl-2 释放树突状细胞介导的肿瘤清除。
Unleashing dendritic cell-mediated tumor clearance by targeting Bcl-2.
发表日期：2023 Oct 07
作者：
Seamus J Martin
来源：
TRENDS IN IMMUNOLOGY
摘要：
Bcl-2 家族蛋白是细胞凋亡的关键调节因子，并且在癌症中经常过度表达。因此，小分子 Bcl-2 拮抗剂（BH3 模拟物）已成为一类新的靶向治疗药物。赵等人最近的一项研究。出人意料地发现 BH3 模拟物还可以激活树突状细胞 (DC)，以启动 T 细胞介导的肿瘤清除。版权所有 © 2023 Elsevier Ltd。保留所有权利。
Bcl-2 family proteins serve as key regulators of apoptosis and are frequently overexpressed in cancer. Consequently, small-molecule Bcl-2-antagonists (BH3 mimetics) have emerged as a new class of targeted therapeutics. A recent study by Zhao et al. has unexpectedly found that BH3 mimetics can also activate dendritic cells (DCs) to prime for T cell-mediated tumor clearance.Copyright © 2023 Elsevier Ltd. All rights reserved.